About us

CeGaT was founded in 2009 in Tübingen, Germany. Our scientists are specialized in next-generation sequencing (NGS) for genetic diagnostics, and we also provide a variety of sequencing services for research purposes and pharma solutions. Our portfolio is complemented by non-sequencing-based methods such as immunomonitoring.

Our dedicated project management team of scientists and bioinformaticians works closely with you to develop the best strategy for the realization of your project. Depending on its scope, we select the most suitable library preparation and sequencing conditions on our Illumina platforms.

We would be pleased to provide you with our award-winning service. Contact us today to start planning your next project.

CeGaT was founded in 2009 in Tübingen, Germany. Our scientists are specialized in next-generation sequencing (NGS) for genetic diagnostics, and we also provide a variety of sequencing services for research purposes and pharma solutions. Our portfolio is complemented by non-sequencing-based methods such as immunomonitoring.

Our dedicated project management team of scientists and bioinformaticians works closely with you to develop the best strategy for the realization of your project. Depending on its scope, we select the most suitable library preparation and sequencing conditions on our Illumina platforms.

We would be pleased to provide you with our award-winning service. Contact us today to start planning your next project.

CeGaT GmbH
Research & Pharma Solutions
Paul-Ehrlich-Str. 23
72076 Tübingen
Germany

Phone: +49 7071 56544-333
Fax: +49 7071 56544-56
Email: ngs@cegat.de

2019/11
Robust immunomonitoring assays are essential for characterizing the immune status of patients receiving novel immunomodulating treatments. The insights gained from studying these immune responses are crucial for bringing promising therapies from the clinical trial phase to standard of care.

CeGaT provides support during initial design, establishment and validation of individual antibody panels and assays for your purposes.

Together with our NGS-based services, we provide a potent immunomonitoring and target discovery platform for your studies.

Excerpts from our immunomonitoring product portfolio

**Blood profiling**
- Determination of relative and absolute counts of peripheral immune cells (T-, B-, NK-cells, MDSCs)
- Using predefined or customized antibody panels

**Phenotypic surface marker analyses**
- Evaluation of activating vs. inhibitory receptors (check-points), exhaustion markers, naive vs. memory status, etc. on defined immune populations

**Functional analyses after stimulation/activation**
- Readout: proliferation (CFSE), cytokine production (Th1, Th2, Th17, CTL), degranulation (killing), protein phosphorylation

**Sequencing of certain immune subpopulations**
- For example CD8+ PD-1+ T-cells

**Detection of (neo)antigen-specific T-cells**
- Detection ex-vivo or after in-vitro expansion
- HLA class I and II using multimer and ICS (Intracellular cytokine staining) technology

**Immunogenicity testing after peptide prediction**
- Enumeration of T-cells capable of recognizing predicted HLA-binding peptides

**Antibody epitope mapping and receptor occupancy testing**
- Characterization and evaluation of antibody-receptor interactions

IFN-γ (x-axis) and TNF (y-axis) production by CD4+ T-cells (left) and CD8+ T-cells (right) activated with Influenza-A-derived peptides (stimulated vs. unstimulated)